Journal News: Telmisartan Not Better Than Placebo in ACE-Inhibitor-Intolerant Patients

The angiotensin-receptor blocker (ARB) telmisartan did no better than placebo in reducing cardiovascular events in high-risk patients intolerant to ACE inhibitors, according to a Lancet study published online.


The international TRANSCEND researchers randomized some 6000 patients with cardiovascular disease or high-risk diabetes to either daily telmisartan or placebo. After a median follow-up of almost 5 years, the primary outcome — a composite of cardiovascular death, MI, stroke, or hospitalization for heart failure — occurred about as frequently among those on telmisartan as those on placebo. (The difference in the primary outcome, minus its heart failure component, achieved borderline statistical significance.)



Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  เปลี่ยนแปลง )

Google+ photo

You are commenting using your Google+ account. Log Out /  เปลี่ยนแปลง )

Twitter picture

You are commenting using your Twitter account. Log Out /  เปลี่ยนแปลง )

Facebook photo

You are commenting using your Facebook account. Log Out /  เปลี่ยนแปลง )


Connecting to %s

%d bloggers like this: